Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roel G.W. Verhaak is active.

Publication


Featured researches published by Roel G.W. Verhaak.


Cancer Cell | 2010

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

Roel G.W. Verhaak; Katherine A. Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D. Wilkerson; C. Ryan Miller; Li Ding; Todd R. Golub; Jill P. Mesirov; Gabriele Alexe; Michael S. Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A. Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S. Feiler; J. Graeme Hodgson; C. David James; Jann N. Sarkaria; Cameron Brennan; Ari Kahn; Paul T. Spellman; Richard Wilson; Terence P. Speed; Joe W. Gray; Matthew Meyerson

The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.


Cell | 2013

The somatic genomic landscape of glioblastoma.

Cameron Brennan; Roel G.W. Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R. Salama; Siyuan Zheng; Debyani Chakravarty; J. Zachary Sanborn; Samuel H. Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill S. Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A. Shukla; Giovanni Ciriello; W.K. Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth D. Aldape; Darell D. Bigner; Erwin G. Van Meir; Michael D. Prados; Andrew E. Sloan; Keith L. Black

We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.


Cancer Cell | 2010

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Houtan Noushmehr; Daniel J. Weisenberger; Kristin Diefes; Heidi S. Phillips; Kanan Pujara; Benjamin P. Berman; Fei Pan; Christopher E. Pelloski; Erik P. Sulman; Krishna P. Bhat; Roel G.W. Verhaak; Katherine A. Hoadley; D. Neil Hayes; Charles M. Perou; Heather K. Schmidt; Li Ding; Richard Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie Cope; Jonathan D. Buckley; James G. Herman; Stephen B. Baylin; Peter W. Laird; Kenneth D. Aldape

We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.


Nature | 2007

Characterizing the cancer genome in lung adenocarcinoma

Barbara A. Weir; Michele S. Woo; Gad Getz; Sven Perner; Li Ding; Rameen Beroukhim; William M. Lin; Michael A. Province; Aldi T. Kraja; Laura A. Johnson; Kinjal Shah; Mitsuo Sato; Roman K. Thomas; Justine A. Barletta; Ingrid B. Borecki; Stephen Broderick; Andrew C. Chang; Derek Y. Chiang; Lucian R. Chirieac; Jeonghee Cho; Yoshitaka Fujii; Adi F. Gazdar; Thomas J. Giordano; Heidi Greulich; Megan Hanna; Bruce E. Johnson; Mark G. Kris; Alex E. Lash; Ling Lin; Neal I. Lindeman

Somatic alterations in cellular DNA underlie almost all human cancers. The prospect of targeted therapies and the development of high-resolution, genome-wide approaches are now spurring systematic efforts to characterize cancer genomes. Here we report a large-scale project to characterize copy-number alterations in primary lung adenocarcinomas. By analysis of a large collection of tumours (n = 371) using dense single nucleotide polymorphism arrays, we identify a total of 57 significantly recurrent events. We find that 26 of 39 autosomal chromosome arms show consistent large-scale copy-number gain or loss, of which only a handful have been linked to a specific gene. We also identify 31 recurrent focal events, including 24 amplifications and 7 homozygous deletions. Only six of these focal events are currently associated with known mutations in lung carcinomas. The most common event, amplification of chromosome 14q13.3, is found in ∼12% of samples. On the basis of genomic and functional analyses, we identify NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung adenocarcinomas. More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered.


Nature Medicine | 2008

Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study

Kerby Shedden; Jeremy M. G. Taylor; Steven A. Enkemann; Ming-Sound Tsao; Timothy J. Yeatman; William L. Gerald; Steven Eschrich; Igor Jurisica; Thomas J. Giordano; David E. Misek; Andrew C. Chang; Chang Qi Zhu; Daniel Strumpf; Samir M. Hanash; Frances A. Shepherd; Keyue Ding; Lesley Seymour; Katsuhiko Naoki; Nathan A. Pennell; Barbara A. Weir; Roel G.W. Verhaak; Christine Ladd-Acosta; Todd R. Golub; Michael Gruidl; Anupama Sharma; Janos Szoke; Maureen F. Zakowski; Valerie W. Rusch; Mark G. Kris; Agnes Viale

Although prognostic gene expression signatures for survival in early-stage lung cancer have been proposed, for clinical application, it is critical to establish their performance across different subject populations and in different laboratories. Here we report a large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The hypotheses proposed examined whether microarray measurements of gene expression either alone or combined with basic clinical covariates (stage, age, sex) could be used to predict overall survival in lung cancer subjects. Several models examined produced risk scores that substantially correlated with actual subject outcome. Most methods performed better with clinical data, supporting the combined use of clinical and molecular information when building prognostic models for early-stage lung cancer. This study also provides the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas.


Nature | 2012

Transformation by the ( R )-enantiomer of 2-hydroxyglutarate linked to EGLN activation

Peppi Koivunen; Sungwoo Lee; Christopher G. Duncan; Giselle Y. Lopez; Gang Lu; Shakti Ramkissoon; Julie-Aurore Losman; Päivi Joensuu; Ulrich Bergmann; Stefan Gross; Jeremy Travins; Samuel Weiss; Ryan E. Looper; Keith L. Ligon; Roel G.W. Verhaak; Hai Yan; William G. Kaelin

The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.


Cell | 2016

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

Michele Ceccarelli; Floris P. Barthel; Tathiane Maistro Malta; Thais S. Sabedot; Sofie R. Salama; Bradley A. Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano Maria Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju C. Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A. Rao; Mia Grifford; Andrew D. Cherniack; Hailei Zhang; Laila M. Poisson; Carlos Gilberto Carlotti; Daniela Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C. Lau; W. K. Alfred Yung; Raul Rabadan; Jason T. Huse; Daniel J. Brat; Norman L. Lehman

Therapy development for adult diffuse glioma is hindered by incomplete knowledge of somatic glioma driving alterations and suboptimal disease classification. We defined the complete set of genes associated with 1,122 diffuse grade II-III-IV gliomas from The Cancer Genome Atlas and used molecular profiles to improve disease classification, identify molecular correlations, and provide insights into the progression from low- to high-grade disease. Whole-genome sequencing data analysis determined that ATRX but not TERT promoter mutations are associated with increased telomere length. Recent advances in glioma classification based on IDH mutation and 1p/19q co-deletion status were recapitulated through analysis of DNA methylation profiles, which identified clinically relevant molecular subsets. A subtype of IDH mutant glioma was associated with DNA demethylation and poor outcome; a group of IDH-wild-type diffuse glioma showed molecular similarity to pilocytic astrocytoma and relatively favorable survival. Understanding of cohesive disease groups may aid improved clinical outcomes.


Cell | 2011

Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma

Chong Liu; Jonathan C. Sage; Michael R. Miller; Roel G.W. Verhaak; Simon Hippenmeyer; Hannes Vogel; Oded Foreman; Roderick T. Bronson; Akiko Nishiyama; Liqun Luo; Hui Zong

Cancer cell of origin is difficult to identify by analyzing cells within terminal stage tumors, whose identity could be concealed by the acquired plasticity. Thus, an ideal approach to identify the cell of origin is to analyze proliferative abnormalities in distinct lineages prior to malignancy. Here, we use mosaic analysis with double markers (MADM) in mice to model gliomagenesis by initiating concurrent p53/Nf1 mutations sporadically in neural stem cells (NSCs). Surprisingly, MADM-based lineage tracing revealed significant aberrant growth prior to malignancy only in oligodendrocyte precursor cells (OPCs), but not in any other NSC-derived lineages or NSCs themselves. Upon tumor formation, phenotypic and transcriptome analyses of tumor cells revealed salient OPC features. Finally, introducing the same p53/Nf1 mutations directly into OPCs consistently led to gliomagenesis. Our findings suggest OPCs as the cell of origin in this model, even when initial mutations occur in NSCs, and highlight the importance of analyzing premalignant stages to identify the cancer cell of origin.


Nature Communications | 2013

Inferring tumour purity and stromal and immune cell admixture from expression data

Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martinez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Trevino; Hui Shen; Peter W. Laird; Douglas A. Levine; Scott L. Carter; Gad Getz; Katherine Stemke-Hale; Gordon B. Mills; Roel G.W. Verhaak

Infiltrating stromal and immune cells form the major fraction of normal cells in tumour tissue and not only perturb the tumour signal in molecular studies but also have an important role in cancer biology. Here we describe ‘Estimation of STromal and Immune cells in MAlignant Tumours using Expression data’ (ESTIMATE)—a method that uses gene expression signatures to infer the fraction of stromal and immune cells in tumour samples. ESTIMATE scores correlate with DNA copy number-based tumour purity across samples from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing and available through The Cancer Genome Atlas. The prediction accuracy is further corroborated using 3,809 transcriptional profiles available elsewhere in the public domain. The ESTIMATE method allows consideration of tumour-associated normal cells in genomic and transcriptomic studies. An R-library is available on https://sourceforge.net/projects/estimateproject/.


Nature | 2011

Suppression of lung adenocarcinoma progression by Nkx2-1

Monte M. Winslow; Talya L. Dayton; Roel G.W. Verhaak; Caroline Kim-Kiselak; Eric L. Snyder; David M. Feldser; Diana Hubbard; Michel DuPage; Charles A. Whittaker; Stephanie Yoon; Denise Crowley; Roderick T. Bronson; Derek Y. Chiang; Matthew Meyerson; Tyler Jacks

Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of KrasLSL-G12D/+;p53flox/flox mice initiates lung adenocarcinoma development. Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.

Collaboration


Dive into the Roel G.W. Verhaak's collaboration.

Top Co-Authors

Avatar

Siyuan Zheng

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Qianghu Wang

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Floris P. Barthel

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Erik P. Sulman

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Tom Mikkelsen

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xin Hu

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Emmanuel Martinez-Ledesma

Monterrey Institute of Technology and Higher Education

View shared research outputs
Top Co-Authors

Avatar

John F. de Groot

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge